Welcome to our dedicated page for Mdxhealth Sa SEC filings (Ticker: MDXH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MDxHealth SA filings document a foreign private issuer focused on precision diagnostics for prostate cancer and other urologic diseases. The company’s Form 6-K reports furnish financial results, interim reports, press releases, governance updates and materials incorporated by reference into registration statements.
The filing record includes shareholder meeting notices, proxy and attendance materials, a share option plan, authorized-capital reports, warrant terms and acquisition-related disclosures. MDXH filings also document the completed Exosome Diagnostics acquisition through audited financial statements and pro forma financial information, along with amendments to earnout obligations related to the GPS acquisition.
AWM Investment Company, Inc. filed an amendment to a Schedule 13G/A reporting no beneficial ownership in MDxHealth (Common Stock). The filing states AWM and related funds hold 0 shares representing 0% of the class (CUSIP B5950S113). The report identifies AWM as adviser to several funds and is signed by Adam Stettner on 07/08/2026.
mdxhealth reported that Nasdaq has notified the company its ordinary shares are out of compliance with the exchange’s $1.00 minimum bid price requirement after trading below that level for 30 consecutive business days. The shares remain listed for now.
The company has 180 calendar days, until December 28, 2026, to regain compliance by achieving a closing bid of at least $1.00 for 10 consecutive business days. mdxhealth may become eligible for an additional 180‑day grace period if it meets other Nasdaq listing standards at that time.
Management is evaluating options, including a potential reverse share split, but states there is no assurance it will restore compliance or avoid delisting, which could materially harm its ability to raise capital and its financial condition.
MDxHealth SA officer Joseph Sollee reported receiving two grants of share options as equity compensation. Each option allows him to purchase ordinary shares at an exercise price of $0.76 per share.
One grant covers 154,100 share options, which vest based on Company performance criteria evaluated by the Board at the end of specified performance periods. The second grant covers 83,000 share options, vesting in three equal annual installments on each of the first three anniversaries of the grant date. Both grants have an expiration date in 2036, providing long-term incentive tied to the Company’s results and his continued service.
MDxHealth SA director Don M. Hardison received a grant of share options as part of his compensation. The award covers 10,000 options to purchase ordinary shares at an exercise price of $0.76 per share, granted on June 1, 2026.
The options vest in full on the date of the annual general shareholders' meeting that takes place in the calendar year after the year of grant and expire on May 28, 2036. Following this grant, Hardison holds 10,000 share options directly.
MDxHealth SA reported that VP of Finance and Accounting Brendan O'Connell received two grants of share options. One grant covers 65,000 options to purchase ordinary shares at an exercise price of $0.76 per share, vesting based on Company performance criteria evaluated by the Board at the end of specified performance periods. A second grant covers 35,000 options at the same $0.76 exercise price, vesting in three equal annual installments on each of the first three anniversaries of the grant date. These awards increase his derivative-based compensation exposure without involving any open-market purchases or sales.
MDxHealth SA Chief Executive Officer Michael McGarrity received two share option awards as equity compensation. He was granted 612,400 options and 329,800 options, each exercisable for ordinary shares at an exercise price of $0.76 per share and expiring on May 28, 2036. One grant vests based on Company performance criteria evaluated by the Board at the end of specified performance periods, while the other vests in three equal annual installments on the first three anniversaries of the grant date. These are grants/awards rather than open‑market purchases or sales, and no dispositions were reported in this filing.
MDxHealth SA director-associated entity receives new stock options. An entity linked to director Hilde Windels, Hilde Windels BV, was granted share options covering 10,000 ordinary shares at an exercise price of $0.76 per share. These options vest in full on the date of the annual general shareholders' meeting held in the calendar year after the grant year and expire on May 28, 2036. Following this grant, 10,000 share options are reported as held indirectly, and the reporting person disclaims beneficial ownership beyond any pecuniary interest in the securities held by Hilde Windels BV.
MDxHealth SA granted Chief Commercial Officer John Bellano a total of share options covering ordinary shares at an exercise price of $0.76 per share. One grant of 217,000 options vests based on Company performance criteria, while a separate 116,000-option grant vests in three equal annual installments from the grant date.
MDxHealth SA director Michael Holder received a grant of share options as compensation. He was awarded options to purchase 10,000 ordinary shares at an exercise price of $0.76 per share, vesting in full on the date of the annual general shareholders' meeting in the calendar year after the grant. Following this grant, he holds 10,000 share options directly, which expire on May 28, 2036. This is a routine equity incentive award rather than an open-market trade.
MDxHealth SA director Sanford Jay Siegel received a grant of share options covering 10,000 ordinary shares. The options have an exercise price of $0.76 per share and were granted as compensation. They vest in full at the annual general shareholders' meeting held in the calendar year after the grant.